AEZS - Aeterna Zentaris Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8004
-0.0256 (-3.10%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8260
Open0.8150
Bid0.5400 x 1200
Ask0.0000 x 1800
Day's Range0.8001 - 0.8400
52 Week Range0.8000 - 5.5700
Volume169,088
Avg. Volume163,775
Market Cap16M
Beta (3Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Aeterna Zentaris Reports Third Quarter 2019 Financial and Operating Results

    CHARLESTON, S.C., Nov. 07, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the third quarter ended September 30,.

  • GlobeNewswire

    Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

    Aeterna Zentaris Inc. (AEZS) (AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective today, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company. Dr. Paulini will continue to be based in Frankfurt, Germany, and his appointment as President and Chief Executive Officer aligns with the Company’s refocus on its operations in Germany.

  • GlobeNewswire

    Aeterna Zentaris Announces Closing of Approximately $5.0 Million Registered Direct Offering

    Aeterna Zentaris Inc. (AEZS) (AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements, announced the closing of its previously announced offering whereby the Company entered into a securities purchase agreement with institutional investors in the United States to purchase approximately $5.0 Million (before placement agent’s fees and expenses) of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement (together, the “Offering”). The combined purchase price for one common share and one warrant was $1.50.

  • GlobeNewswire

    Aeterna Zentaris Announces Pricing of Approximately $5.0 Million Registered Direct Offering

    Aeterna Zentaris Inc.Aeterna Zentaris Inc. (AEZS) (AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements, announced today that it has entered into a securities purchase agreement with institutional investors in the United States to purchase approximately $5.0 million of its common shares in a registered direct offering and warrants to purchase common shares in a concurrent private placement. The combined purchase price for one common share and one warrant will be $1.50. Under the terms of the securities purchase agreement, Aeterna has agreed to sell 3,325,000 shares of its common shares.

  • GlobeNewswire

    Aeterna Zentaris Announces Director Change

    CHARLESTON, S.C., Aug. 20, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that Jonathan Pollack has resigned as a director of the Company for personal.

  • GlobeNewswire

    Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results

    CHARLESTON, S.C., Aug. 13, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the second quarter ended June 30,.

  • GlobeNewswire

    Aeterna Zentaris Provides Corporate Update

    Aeterna Zentaris Inc. (AEZS) (AEZS) today announced that it is reducing the size of its German workforce and operations to more closely reflect the Company's ongoing commercial activities in Frankfurt. The Company is also providing an update on the previously disclosed securities class action lawsuit pending in the U.S. District Court for the District of New Jersey, brought on behalf of shareholders of the Company. The lawsuit alleges violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between August 30, 2011 and November 6, 2014 regarding the safety and efficacy of Macrilen™ (macimorelin) and the prospects for the approval of the Company's New Drug Application for the product by the FDA.

  • GlobeNewswire

    Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting

    CHARLESTON, S.C., May 08, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) announced today at its annual and special shareholders’ meeting held on May 8, 2019, that the.

  • GlobeNewswire

    Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results

    CHARLESTON, S.C., May 07, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the first quarter ended March 31,.

  • GlobeNewswire

    Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results

    Aeterna Zentaris Inc. (AEZS) (AEZS) today reported its financial and operating results for the fourth quarter and year ended December 31, 2018. The increase in total revenue in 2018 relates to license fees, royalty income and product sales associated with executing the License and Assignment Agreement for Macrilen™ (macimorelin) in January 2018.

  • GlobeNewswire

    Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019

    Aeterna Zentaris Inc. (AEZS) (AEZS) will announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March 26, 2019. Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies, principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada.

  • GlobeNewswire

    Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor

    Aeterna Zentaris Inc. (AEZS) (AEZS) announced today that its board of directors has formed a special committee of independent directors (the “Special Committee”) to review strategic options available to Aeterna Zentaris. The Special Committee has approved the engagement by the Company of Torreya, a global investment bank specializing in life sciences, as its financial advisor.  Torreya is working with management to assist the Special Committee and the board of directors in considering a wide range of transactions (including opportunities for the license of macimorelin outside of the United States and Canada, other monetization transactions relating to macimorelin or the potential sale of the company) which may create value for the company, its shareholders and other stakeholders.

  • GlobeNewswire

    Aeterna Zentaris Receives European Marketing Clearance for Macimorelin

    Aeterna Zentaris Inc. (AEZS) (AEZS) announced that the European Medicines Agency (EMA) has granted marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD).  “Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition,” said Dr. Christian Strasburger, the Head of Clinical Endocrinology at Charité Unversitaetsmedizin Berlin and the principal investigator for macimorelin. AGHD may occur in an adult subject who has a history of childhood onset growth hormone deficiency (GHD) or may occur during adulthood as an acquired condition.

  • GlobeNewswire

    Aeterna Zentaris Settles Dispute with David Dodd and Philip Theodore

    CHARLESTON, S.C., Dec. 21, 2018 -- Aeterna Zentaris Inc., (NASDAQ:AEZS) (TSX: AEZS) has settled its previously disclosed litigation in South Carolina and Canada with former.